- Report
- February 2024
- 250 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- April 2024
- 190 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- May 2022
- 196 Pages
Global
From €5067EUR$5,250USD£4,347GBP
- Report
- October 2022
- 270 Pages
Global
From €3619EUR$3,750USD£3,105GBP
- Report
- September 2022
- 232 Pages
Global
From €3378EUR$3,500USD£2,898GBP
- Report
- August 2022
- 111 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- June 2022
- 120 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2654EUR$2,750USD£2,277GBP
- Report
- September 2022
- 282 Pages
Global
From €9169EUR$9,500USD£7,866GBP
- Report
- February 2022
- 228 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- February 2022
- 210 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- January 2023
- 116 Pages
Global
From €4343EUR$4,500USD£3,726GBP
- Report
- August 2022
- 118 Pages
Global
From €4343EUR$4,500USD£3,726GBP
- Report
- September 2021
- 111 Pages
Global
From €4343EUR$4,500USD£3,726GBP
- Report
- April 2018
Global
From €4343EUR$4,500USD£3,726GBP
- Drug Pipelines
- July 2018
- 27 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Drug Pipelines
- May 2018
- 79 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- April 2018
United States
From €7717EUR$7,995USD£6,619GBP
- Drug Pipelines
- August 2018
- 610 Pages
Global
From €21234EUR$22,000USD£18,215GBP
Certolizumab is a monoclonal antibody used to treat immune disorders. It is used to treat a variety of conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. It works by blocking the action of a protein called tumor necrosis factor (TNF), which is involved in the body's inflammatory response. Certolizumab is administered as an injection, usually once every two weeks.
Certolizumab is a relatively new drug, having been approved by the US Food and Drug Administration in 2008. It is one of several drugs used to treat immune disorders, and is often used in combination with other medications. It is generally well-tolerated, with few side effects.
Some companies in the Certolizumab market include UCB, Pfizer, and AbbVie. Show Less Read more